---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-064530"
form_type: "8-K"
ticker: null
cik: "0001907685"
company_name: "Comera Life Sciences Holdings, Inc."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T01:32:47.679734+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Comera Life Sciences receives Nasdaq delisting notice; no appeal; securities to move to OTC Markets

## Summary
- Nasdaq Hearings Panel determined to delist common stock (CMRA) and warrants (CMRAW) effective Nov 17, 2023.
- Company will not appeal; expects Form 25-NSE to be filed with SEC.
- Failure to regain compliance with MVLS ($35M minimum) and minimum bid price ($1.00) by Nov 14, 2023.
- Common stock and warrants expected to trade on OTC Markets under same symbols starting Nov 17; applied for OTCQB.

## SEC filing metadata
- accession: 0000950170-23-064530
- form_type: 8-K
- cik: 0001907685
- company_name: Comera Life Sciences Holdings, Inc.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907685/000095017023064530/0000950170-23-064530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907685/000095017023064530/cmra-20231115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-064530
- JSON: https://secwatch.observer/filing/0000950170-23-064530.json
- Plain text: https://secwatch.observer/filing/0000950170-23-064530.txt

## Key facts
- Listing & Compliance Notices
  Comera Life Sciences Holdings, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: q Stock Market on November 18, 2022 notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2). On August 8, 2023, the Nasdaq Hearings Panel granted the Company’s request for the continued listing of its common stock on the Nasdaq Capital Market, subject to the Company’s satisfaction of certain interim milestones and, ultimately, the Company’s compliance with all applicable criteri
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907685/000095017023064530/0000950170-23-064530-index.htm
- Listing & Compliance Notices
  Comera Life Sciences Holdings, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: October 31, 2023, the Company received an additional delist determination for failing to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market (the “bid price requirement”), as set forth in Nasdaq Listing Rule 5550(a)(2) within the 180 calendar day period provided by Rule 5810(c)(3)(A). The Company was unable to regain compliance with the MVLS Rule or any of the alternative standards for continued listing in Nasdaq Listing Rule 5550(b) by November 14, 2023. Following the delisting of its securities from the Nasdaq Capital Market, the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1907685/000095017023064530/0000950170-23-064530-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.